3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More

18
16
Favorite

3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More

Motley Fool2021-04-14

Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（16）

SSVC
·2021-04-15
Nice Appreciate your response and comments Thanks
Reply
1
Report
Fold Replies
- PJoo:
  [握手]
  2021-04-15
  Reply
  Report
EstherPang
·2021-04-15
Good, go go buy
Reply
5
Report
Fold Replies
- 向上学习:
  [微笑]
  2021-04-15
  Reply
  Report
- EstherPang:
  [龇牙]
  2021-04-15
  Reply
  Report
Darrenneoyo
·2021-04-14
What about PLTR?
Reply
Like
Report
Fold Replies
- Darrenneoyo:
  double click day baby
  2021-04-14
  Reply
  Report
Kimobin
·2021-04-14
Buy?
Reply
1
Report
Fold Replies
- Kimoqi:
  ok
  2021-04-14
  Reply
  Report
Lammie
·2021-04-14
Nice
Reply
Like
Report
MrGreen
·2021-04-14
Nice
Reply
Like
Report
March_m
·2021-04-14
How safe is the vaccine now?
Reply
Like
Report
Ahwei6868
·2021-04-14
$
Reply
3
Report
hairzzgirl
·2021-04-14
Naise
Reply
Like
Report
kerukel88
·2021-04-14
Nice
Reply
1
Report
jingabel
·2021-04-14
Maybe maybe
Reply
Like
Report
Showcase
·2021-04-14
Nice
Reply
Like
Report
Fold Replies
- windspring:
  wow
  2021-04-16
  Reply
  Report
Annalz
·2021-04-14
No need to take responsibility anyway
Reply
Like
Report
Andaroo
·2021-04-14
AMC gme
Reply
2
Report
Jesss
·2021-04-14
Mmm...
Reply
1
Report
Han96
·2021-04-14
Like and comment
Reply
3
Report
Fold Replies
- KopiLim:
  For me too
  2021-04-14
  Reply
  Report
- wc77:
  for me too
  2021-04-14
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2127026644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-14 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2127026644","market":"us","top_or_hot":-1,"title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","media":"Motley Fool","content":"<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRUP","symbol_name":"Trupanion","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","article_id":"2127026644","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","pubTimestamp":1618394400,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Analysts' enthusiasm for these stocks appears to be justified.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRUP":"Trupanion"},"translate_title":"华尔街认为将飙升50%或以上的3只股票可买入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRUP":0.9},"content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":344797521,"gmtCreate":1618442343063,"gmtModify":1704710816302,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"Nice Appreciate your response and comments Thanks&nbsp;","listText":"Nice Appreciate your response and comments Thanks&nbsp;","text":"Nice Appreciate your response and comments Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/344797521","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4043265,"gmtCreate":1618485589283,"gmtModify":1680784180087,"authorId":3572863479502236,"author":{"id":3572863479502236,"idStr":"3572863479502236","authorId":3572863479502236,"name":"PJoo","avatar":"https://static.tigerbbs.com/c1df329f4341646fc633446858d34c31","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344797521,"type":1,"supId":0,"prevId":0,"content":"[握手]","text":"[握手]","html":"[握手]"}],"langContent":"EN"},{"id":344475476,"gmtCreate":1618440700795,"gmtModify":1704710784972,"author":{"id":"3576365817943823","authorId":"3576365817943823","name":"EstherPang","avatar":"https://static.tigerbbs.com/8990239e19377757a2b24cf2333a310d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576365817943823","authorIdStr":"3576365817943823"},"htmlText":"Good, go go buy","listText":"Good, go go buy","text":"Good, go go buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/344475476","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4037766,"gmtCreate":1618440791782,"gmtModify":1680784091922,"authorId":3576884869412058,"author":{"id":3576884869412058,"idStr":"3576884869412058","authorId":3576884869412058,"name":"向上学习","avatar":"https://static.tigerbbs.com/a70af8809a95756364cc82fcfde2f404","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344475476,"type":1,"supId":0,"prevId":0,"content":"[微笑]","text":"[微笑]","html":"[微笑]"},{"id":4037982,"gmtCreate":1618442021993,"gmtModify":1680784089264,"authorId":3576365817943823,"author":{"id":3576365817943823,"idStr":"3576365817943823","authorId":3576365817943823,"name":"EstherPang","avatar":"https://static.tigerbbs.com/8990239e19377757a2b24cf2333a310d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344475476,"type":1,"supId":4037766,"prevId":0,"content":"[龇牙]","text":"[龇牙]","html":"[龇牙]"}],"langContent":"EN"},{"id":344211419,"gmtCreate":1618409797731,"gmtModify":1704710425670,"author":{"id":"3572866150582582","authorId":"3572866150582582","name":"Darrenneoyo","avatar":"https://static.tigerbbs.com/19498d498955308da03ff537c16af7b0","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":5,"crmLevelSwitch":1,"idStr":"3572866150582582","authorIdStr":"3572866150582582"},"htmlText":"What about PLTR?","listText":"What about PLTR?","text":"What about PLTR?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/344211419","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4035051,"gmtCreate":1618409818541,"gmtModify":1680784053234,"authorId":3572866150582582,"author":{"id":3572866150582582,"idStr":"3572866150582582","authorId":3572866150582582,"name":"Darrenneoyo","avatar":"https://static.tigerbbs.com/19498d498955308da03ff537c16af7b0","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.33%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344211419,"type":1,"supId":0,"prevId":0,"content":"double click day <u>baby</u>","text":"double click day <u>baby</u>","html":"double click day <u>baby</u>"}],"langContent":"EN"},{"id":344622763,"gmtCreate":1618407535352,"gmtModify":1704710333522,"author":{"id":"3579305701715904","authorId":"3579305701715904","name":"Kimobin","avatar":"https://community-static.tradeup.com/news/6a2da3e1b9852b8281d5a59c7ef4f0da","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3579305701715904","authorIdStr":"3579305701715904"},"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/344622763","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4034543,"gmtCreate":1618407598243,"gmtModify":1680784047368,"authorId":3579307827566708,"author":{"id":3579307827566708,"idStr":"3579307827566708","authorId":3579307827566708,"name":"Kimoqi","avatar":"https://static.tigerbbs.com/4a75a25c05f3caeb1708eff0d5b7effc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344622763,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":344689600,"gmtCreate":1618406027000,"gmtModify":1704710294635,"author":{"id":"3579863048316157","authorId":"3579863048316157","name":"Lammie","avatar":"https://static.tigerbbs.com/22f853e264a96287b9819a7a9d2d2f84","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579863048316157","authorIdStr":"3579863048316157"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344689600","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344689115,"gmtCreate":1618406022437,"gmtModify":1704710294957,"author":{"id":"3576511277084418","authorId":"3576511277084418","name":"MrGreen","avatar":"https://static.tigerbbs.com/15d34383baa6cc8886d9224669a807d4","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3576511277084418","authorIdStr":"3576511277084418"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344689115","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344631291,"gmtCreate":1618404642813,"gmtModify":1704710271834,"author":{"id":"3580437128970359","authorId":"3580437128970359","name":"March_m","avatar":"https://static.tigerbbs.com/c79c26d5f3dd57115bbcf794ff43dff2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580437128970359","authorIdStr":"3580437128970359"},"htmlText":"How safe is the vaccine now?&nbsp;","listText":"How safe is the vaccine now?&nbsp;","text":"How safe is the vaccine now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344631291","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344639853,"gmtCreate":1618404536472,"gmtModify":1704710268588,"author":{"id":"3576210449115034","authorId":"3576210449115034","name":"Ahwei6868","avatar":"https://static.tigerbbs.com/1fd3c758c9658a33289fa552d6d0f3d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576210449115034","authorIdStr":"3576210449115034"},"htmlText":"$","listText":"$","text":"$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344639853","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344697230,"gmtCreate":1618404354920,"gmtModify":1704710266318,"author":{"id":"3576033663537145","authorId":"3576033663537145","name":"hairzzgirl","avatar":"https://static.tigerbbs.com/c73862868c1d27e931dbc124cbf08fce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576033663537145","authorIdStr":"3576033663537145"},"htmlText":"Naise","listText":"Naise","text":"Naise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344697230","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344695466,"gmtCreate":1618404203055,"gmtModify":1704710263729,"author":{"id":"3580376639553291","authorId":"3580376639553291","name":"kerukel88","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580376639553291","authorIdStr":"3580376639553291"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344695466","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344604932,"gmtCreate":1618403354026,"gmtModify":1704710249888,"author":{"id":"3579683280519440","authorId":"3579683280519440","name":"jingabel","avatar":"https://static.tigerbbs.com/5109716c64f0b691a5098e4d5397ffc2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579683280519440","authorIdStr":"3579683280519440"},"htmlText":"Maybe maybe","listText":"Maybe maybe","text":"Maybe maybe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344604932","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344878924,"gmtCreate":1618401795168,"gmtModify":1704710229477,"author":{"id":"3578739466550787","authorId":"3578739466550787","name":"Showcase","avatar":"https://static.tigerbbs.com/48864a971d3cf33ae9e4aed6b49688bc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578739466550787","authorIdStr":"3578739466550787"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/344878924","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4046590,"gmtCreate":1618520773657,"gmtModify":1680784230350,"authorId":3575962000596639,"author":{"id":3575962000596639,"idStr":"3575962000596639","authorId":3575962000596639,"name":"windspring","avatar":"https://community-static.tradeup.com/news/9db5e6cf6f2c0772fd2a8ed3eec6b8f9","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.78%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344878924,"type":1,"supId":0,"prevId":0,"content":"<u>wow</u>","text":"<u>wow</u>","html":"<u>wow</u>"}],"langContent":"EN"},{"id":344871480,"gmtCreate":1618401744140,"gmtModify":1704710228993,"author":{"id":"3577089953267281","authorId":"3577089953267281","name":"Annalz","avatar":"https://static.tigerbbs.com/ffd285ab6189bb61da4b48c3e149eedc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3577089953267281","authorIdStr":"3577089953267281"},"htmlText":"No need to take responsibility anyway","listText":"No need to take responsibility anyway","text":"No need to take responsibility anyway","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344871480","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344887972,"gmtCreate":1618397490096,"gmtModify":1704710165854,"author":{"id":"3575199303759784","authorId":"3575199303759784","name":"Andaroo","avatar":"https://static.tigerbbs.com/634c9b9f18158d4a4e497249bdbe8fd5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575199303759784","authorIdStr":"3575199303759784"},"htmlText":"AMC gme","listText":"AMC gme","text":"AMC gme","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344887972","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344885534,"gmtCreate":1618397267928,"gmtModify":1704710163212,"author":{"id":"3581132427981586","authorId":"3581132427981586","name":"Jesss","avatar":"https://static.tigerbbs.com/3d97fa229afbb5213f7f41ad230a8825","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581132427981586","authorIdStr":"3581132427981586"},"htmlText":"Mmm...","listText":"Mmm...","text":"Mmm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344885534","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":344815266,"gmtCreate":1618396135155,"gmtModify":1704710148315,"author":{"id":"3569371789291180","authorId":"3569371789291180","name":"Han96","avatar":"https://static.tigerbbs.com/f97b8f049cf05e776dde087d8f933617","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569371789291180","authorIdStr":"3569371789291180"},"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/344815266","repostId":2127026644,"repostType":4,"repost":{"id":"2127026644","pubTimestamp":1618394400,"share":"https://ttm.financial/m/news/2127026644?lang=&edition=fundamental","pubTime":"2021-04-14 18:00","market":"us","language":"en","title":"3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2127026644","media":"Motley Fool","summary":"Analysts' enthusiasm for these stocks appears to be justified.","content":"<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.</p><p>Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621139%2F3-blue-arrows.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"496\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Nano-X Imaging</h3><p>The average analysts' <a href=\"https://laohu8.com/S/AONE\">one</a>-year price target for&nbsp;<b>Nano-X Imaging</b> (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.</p><p>Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.</p><p>The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.</p><p>To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.</p><h3>Novavax</h3><p><b>Novavax</b> (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.</p><p>Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.</p><p>Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.</p><p>Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.</p><h3><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></h3><p>Analysts also foresee success for&nbsp;<b>Trupanion</b> (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.</p><p>Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.</p><p>However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.</p><p>Beyond 2021, Trupanion's relationship with <b>Aflac</b>&nbsp;could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 18:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion"},"source_url":"https://www.fool.com/investing/2021/04/14/3-stocks-to-buy-that-wall-street-thinks-will-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127026644","content_text":"Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.Image source: Getty Images.Nano-X ImagingThe average analysts' one-year price target for Nano-X Imaging (NASDAQ:NNOX) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner.The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market.To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.NovavaxNovavax (NASDAQ:NVAX) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain.Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021.Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.TrupanionAnalysts also foresee success for Trupanion (NASDAQ:TRUP). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4033260,"gmtCreate":1618396405203,"gmtModify":1680784022019,"authorId":3562886608344748,"author":{"id":3562886608344748,"idStr":"3562886608344748","authorId":3562886608344748,"name":"KopiLim","avatar":"https://static.tigerbbs.com/04fcef53a2e715c173a40fafa14a7fe6","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344815266,"type":1,"supId":0,"prevId":0,"content":"For me too","text":"For me too","html":"For me too"},{"id":4033339,"gmtCreate":1618397287660,"gmtModify":1680784018168,"authorId":3576029059404897,"author":{"id":3576029059404897,"idStr":"3576029059404897","authorId":3576029059404897,"name":"wc77","avatar":"https://static.tigerbbs.com/9ece187c7197f1ec611a9df7730f776e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":344815266,"type":1,"supId":0,"prevId":0,"content":"for me too","text":"for me too","html":"for me too"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":18,"commentSize":16,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}